{"id":57897,"date":"2026-02-25T13:15:27","date_gmt":"2026-02-25T05:15:27","guid":{"rendered":"https:\/\/flcube.com\/?p=57897"},"modified":"2026-02-25T13:15:29","modified_gmt":"2026-02-25T05:15:29","slug":"insilico-medicine-partners-with-mskcc-to-discover-gastroesophageal-cancer-targets-ai-driven-multi-omics-analysis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57897","title":{"rendered":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis"},"content":{"rendered":"\n<p><strong>Insilico Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG:\u202f3696<\/a>)<\/strong> announced a <strong>collaboration agreement<\/strong> with <strong>Memorial Sloan Kettering Cancer Center (MSKCC)<\/strong> to jointly discover <strong>novel therapeutic targets<\/strong> for <strong>gastroesophageal cancers (GEC)<\/strong>. The partnership combines MSKCC&#8217;s <strong>high\u2011quality patient multi\u2011omics and clinical data<\/strong> with Insilico&#8217;s <strong>PandaOmics AI platform<\/strong> to accelerate target identification across GEC subtypes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner 1<\/strong><\/td><td>Insilico Medicine (HKG:\u202f3696) \u2013 AI\u2011driven drug discovery<\/td><\/tr><tr><td><strong>Partner 2<\/strong><\/td><td>Memorial Sloan Kettering Cancer Center (MSKCC)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Joint target discovery partnership<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Gastroesophageal cancers (GEC)<\/td><\/tr><tr><td><strong>Data Resources<\/strong><\/td><td>Genomic, proteomic, transcriptomic + deeply annotated clinical cohorts<\/td><\/tr><tr><td><strong>AI Platform<\/strong><\/td><td>PandaOmics (Insilico&#8217;s proprietary AI biology platform)<\/td><\/tr><tr><td><strong>Platform Capabilities<\/strong><\/td><td>20+ in\u2011house AI and bioinformatics models<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-workflow\">Collaboration Workflow<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Activity<\/th><th>Responsible Party<\/th><\/tr><\/thead><tbody><tr><td><strong>1. Data Provision<\/strong><\/td><td>Access to high\u2011quality patient multi\u2011omics and clinical data resources<\/td><td>MSKCC<\/td><\/tr><tr><td><strong>2. Data Integration<\/strong><\/td><td>Systematic analysis of disease drivers across GEC subtypes<\/td><td>Joint<\/td><\/tr><tr><td><strong>3. AI Analysis<\/strong><\/td><td>PandaOmics platform integration; AI\u2011driven target hypothesis generation<\/td><td>Insilico Medicine<\/td><\/tr><tr><td><strong>4. Target Prioritization<\/strong><\/td><td>Prioritize biological targets with high translational potential and drugability<\/td><td>Insilico Medicine<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-assets\">Strategic Assets<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mskcc-data-resources\">MSKCC Data Resources<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Genomic Data:<\/strong> Comprehensive tumor sequencing profiles<\/li>\n\n\n\n<li><strong>Proteomic Data:<\/strong> Protein expression and pathway activation patterns<\/li>\n\n\n\n<li><strong>Transcriptomic Data:<\/strong> Gene expression signatures across GEC subtypes<\/li>\n\n\n\n<li><strong>Clinical Cohorts:<\/strong> Deeply annotated patient outcomes and treatment responses<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-insilico-pandaomics-platform\">Insilico PandaOmics Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Models:<\/strong> 20+ proprietary AI and bioinformatics algorithms<\/li>\n\n\n\n<li><strong>Function:<\/strong> Systematic target prioritization based on translational potential and drugability<\/li>\n\n\n\n<li><strong>Integration:<\/strong> Multi\u2011omics data fusion with proprietary discovery tools<\/li>\n\n\n\n<li><strong>Output:<\/strong> Novel disease mechanisms and validated target hypotheses<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data\u2011Driven Discovery:<\/strong> MSKCC&#8217;s <strong>deep clinical and molecular datasets<\/strong> provide the foundation for unbiased, systematic analysis of GEC biology\u2014moving beyond single\u2011gene approaches to network\u2011level understanding.<\/li>\n\n\n\n<li><strong>AI Acceleration:<\/strong> PandaOmics&#8217; <strong>20+ AI models<\/strong> can process complex multi\u2011omics data at scale, identifying non\u2011obvious target\u2011disease relationships that traditional methods may miss.<\/li>\n\n\n\n<li><strong>Translational Focus:<\/strong> The platform prioritizes targets with <strong>high drugability and clinical translatability<\/strong>, reducing attrition risk in downstream development.<\/li>\n\n\n\n<li><strong>GEC Unmet Need:<\/strong> Gastroesophageal cancers represent <strong>aggressive malignancies<\/strong> with limited targeted therapy options; novel target discovery could unlock breakthrough treatments.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Drug Discovery Validation:<\/strong> The MSKCC partnership validates Insilico&#8217;s <strong>PandaOmics platform<\/strong> as a tool for serious oncology target discovery, beyond the company&#8217;s internal pipeline applications.<\/li>\n\n\n\n<li><strong>Academic\u2011Industry Model:<\/strong> The collaboration exemplifies a <strong>data\u2011sharing framework<\/strong> between leading cancer centers and AI biotechs, potentially replicable across other tumor types.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Successful target discovery could yield <strong>licensable assets<\/strong> or form the basis for Insilico&#8217;s expanded internal GEC therapeutic programs.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding target discovery timelines, validation success, and therapeutic development potential. Actual results may differ due to risks including data integration challenges, target validation outcomes, and competitive dynamics in oncology drug discovery.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,93],"tags":[99,16,4514,164],"class_list":["post-57897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-digital","tag-ai","tag-cancer","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC&#039;s high\u2011quality patient multi\u2011omics and clinical data with Insilico&#039;s PandaOmics AI platform to accelerate target identification across GEC subtypes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57897\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC&#039;s high\u2011quality patient multi\u2011omics and clinical data with Insilico&#039;s PandaOmics AI platform to accelerate target identification across GEC subtypes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57897\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T05:15:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T05:15:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis\",\"datePublished\":\"2026-02-25T05:15:27+00:00\",\"dateModified\":\"2026-02-25T05:15:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2501.webp\",\"keywords\":[\"AI\",\"Cancer\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57897#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57897\",\"name\":\"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2501.webp\",\"datePublished\":\"2026-02-25T05:15:27+00:00\",\"dateModified\":\"2026-02-25T05:15:29+00:00\",\"description\":\"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC's high\u2011quality patient multi\u2011omics and clinical data with Insilico's PandaOmics AI platform to accelerate target identification across GEC subtypes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57897\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57897#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC's high\u2011quality patient multi\u2011omics and clinical data with Insilico's PandaOmics AI platform to accelerate target identification across GEC subtypes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57897","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis","og_description":"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC's high\u2011quality patient multi\u2011omics and clinical data with Insilico's PandaOmics AI platform to accelerate target identification across GEC subtypes.","og_url":"https:\/\/flcube.com\/?p=57897","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T05:15:27+00:00","article_modified_time":"2026-02-25T05:15:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57897#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57897"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis","datePublished":"2026-02-25T05:15:27+00:00","dateModified":"2026-02-25T05:15:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57897"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57897#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","keywords":["AI","Cancer","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57897#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57897","url":"https:\/\/flcube.com\/?p=57897","name":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57897#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57897#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","datePublished":"2026-02-25T05:15:27+00:00","dateModified":"2026-02-25T05:15:29+00:00","description":"Insilico Medicine (HKG:\u202f3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to jointly discover novel therapeutic targets for gastroesophageal cancers (GEC). The partnership combines MSKCC's high\u2011quality patient multi\u2011omics and clinical data with Insilico's PandaOmics AI platform to accelerate target identification across GEC subtypes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57897#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57897"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57897#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","width":1080,"height":608,"caption":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57897#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets \u2013 AI\u2011Driven Multi\u2011Omics Analysis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57897"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57897\/revisions"}],"predecessor-version":[{"id":57899,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57897\/revisions\/57899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57898"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}